Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Can This 1 Thing Hurt Vaxart?

TheMotleyFool

0 0

Vaxart (NASDAQ: VXRT) has been involved in the coronavirus vaccine race since the beginning. It's developing what could be a game-changing option: a vaccine in pill form. That's why this biotech player has been one to watch.

That potential product is now involved in phase 2 studies. That's as rivals Pfizer and Moderna have gained dominance in the market worldwide. And latecomer Novavax even reported its first quarterly profit recently -- after just one quarter of selling its vaccine.

All of this means there is one big problem for Vaxart right now. The question is: Could it hurt the company's prospects over the long term? Let's find out.

Source Fool.com

Like: 0

VXRT

Share